Which large pharma might make the next move in the VEGF bispecific race?

Summit Therapeutics licensed its PD-1xVEGF bispecific antibody ivonescimab from the Chinese company Akeso back in 2022. But analysts believe that the US biotech needs to find another, even bigger partner to bring ...